NAMS earnings analysis
What we found in NAMS's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
NAMS reported Q2 2026 revenue of $3.7 million, down 81% year over year from $19.1 million as prior-year Menarini development funding did not recur; sequentially, revenue increased from an implied $3.0 million in Q1 based on the reported six-month total of $6.7 million. The net loss widened to $64.1 million from $17.4 million, driven by a 52% increase in R&D spending to $41.7 million, a warrant fair-value loss and unfavorable foreign exchange. The company retains $678.3 million of cash, cash equivalents and marketable securities, but valuation and outlook hinge on European approvals and the Q4 2026 PREVAIL interim analysis. No EPS, gross margin, segment revenue, capex, or explicit financial guidance was disclosed in the provided filing text.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- $678.3M liquidity and lower operating cash burn
- Liquidity remains substantial at $678.3 million of cash, cash equivalents and marketable securities as of June 30, 2026. First-half operating cash use improved to $69.8 million from $74.1 million a year earlier, while the company states this cash is sufficient for its estimated $50.6 million of commitments due within one year and $11.4 million due thereafter.
- European approval path advances
- The EMA's CHMP issued a positive opinion in July 2026 for both obicetrapib 10 mg monotherapy and the 10 mg/10 mg obicetrapib-ezetimibe FDC. If approvals are received, Menarini could launch in Germany and the UK in Q4 2026.
- R&D supports advancing pipeline
- Clinical investment accelerated: Q2 clinical expense increased $11.1 million year over year to $24.0 million, contributing to a $14.2 million, or 52%, increase in total R&D expense to $41.7 million as trials were initiated and ongoing studies progressed.
- Major CV outcomes catalyst scheduled
- PREVAIL enrolled at least 9,000 patients and management plans a blinded DSMB interim analysis in Q4 2026 after the last participant reaches the minimum 2.5-year follow-up period. A DSMB recommendation is expected in Q1 2027.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Revenue declined 81% as license income lapped
- Q2 revenue fell 81% year over year to $3.7 million from $19.1 million because the prior-year period included $16.1 million from Menarini's second development-cost installment that did not recur. The filing does not report product-sales revenue or segment revenue, underscoring reliance on collaboration-related income before approval.
- Losses and operating margin deteriorated sharply
- The quarterly loss widened to $64.1 million from $17.4 million and operating loss expanded to $64.9 million from $35.6 million. Operating margin was -1,752.6% on $3.7 million of revenue, versus -186.1% a year earlier; EPS was not disclosed in the provided filing text.
- PREVAIL interim analysis carries futility risk
- A newly updated risk factor cautions that preliminary blinded PREVAIL trends may change as events are identified and adjudicated. The Q4 2026 interim analysis could lead the DSMB to recommend stopping for futility; if it continues, completion is expected only by the end of 2027.
- New reimbursement pressure could limit pricing
- The updated healthcare-policy risk notes that Medicare may negotiate prices for 20 high-cost drugs annually beginning in 2029, while the redesigned Part D benefit requires manufacturer subsidies of 10% below and 20% above the out-of-pocket maximum. These measures could constrain pricing and reimbursement if obicetrapib is approved.
- Tariff changes threaten supply costs
- The updated trade-policy risk cites a 10% baseline U.S. tariff imposed in April 2025 and a new worldwide tariff effective for 150 days from February 24, 2026. Tariffs on pharmaceutical ingredients or finished products could increase manufacturing costs and disrupt supply.
- Cash declined amid continuing development losses
- Cash, cash equivalents and restricted cash declined to $425.5 million at June 30, 2026 from $491.3 million at the start of the year. Management reports $875.0 million of accumulated losses and expects significant losses for the foreseeable future.
What they reported.
What the company itself reported, taken out of the document.
- Operating margin
- -1752.6%
What they said about what is next.
No quantitative financial revenue or EPS guidance was provided in the 10-Q. Management expects regulatory decisions on Menarini's European, UK and Swiss MAAs later in 2026; potential Germany and UK launches could occur in Q4 2026 if approved. PREVAIL's DSMB interim analysis is planned for Q4 2026, with a recommendation expected in Q1 2027; if the trial continues, management expects completion by the end of 2027.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 7, 2026
- NAMS reported revenue of $3.0 million for Q1 2026, consistent with the prior year, despite significant operating losses. Operating expenses decreased over the period, leading to a narrower operating loss of $58.4…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing NAMS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever